The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer

The anti-androgen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration resistant PCa (CRPC) is limited. We previously showed that resistance to bicalutamide results from activation of mechanistic target of rapamycin (mTOR). In...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Abronzo, Leandro S., Bose, Swagata, Crapuchettes, Michael E., Beggs, Ryan E., Vinall, Ruth L., Tepper, Clifford G., Siddiqui, Salma, Mudryj, Maria, Melgoza, Frank U., Durbin-Johnson, Blythe P., deVere White, Ralph W., Ghosh., Paramita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690844/
https://www.ncbi.nlm.nih.gov/pubmed/28745319
http://dx.doi.org/10.1038/onc.2017.233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690844/
https://www.ncbi.nlm.nih.gov/pubmed/28745319
http://dx.doi.org/10.1038/onc.2017.233

Ejemplares similares